Document is current
Any future updates will be listed below
-
Authors
Greten, Tim F. http://orcid.org/0000-0002-0806-2535
Schwabe, Robert http://orcid.org/0000-0003-4571-2098
Bardeesy, Nabeel http://orcid.org/0000-0003-3867-0416
Ma, Lichun
Goyal, Lipika
Kelley, Robin K. http://orcid.org/0000-0002-1984-2430
Wang, Xin W.
- License Information
-
More Information
Article History
Accepted: 23 December 2022
First Online: 25 January 2023
Competing interests
: R.K.K. has received research funding (to institution) from Agios, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, EMD Serono, Exelixis, Genentech/Roche, Loxo Oncology, Merck, Novartis, Partner Therapeutics, QED, Relay Therapeutics, Surface Oncology and Taiho Oncology. R.K.K. has received payments for consulting or advisory board membership (to institution) from Agios, AstraZeneca, Exelixis, Ipsen, Merck and (to self) from Exact Sciences and Kinnate. L.G. has received research funding (to institution) from Adaptimmune, Bayer, Eisai, Merck, Macrogenics, Genentech, Novartis, Incyte, Eli Lilly, Loxo Oncology, Relay Therapeutics, QED, Servier, Taiho Oncology, Leap Therapeutics, Bristol Myers Squibb and Nucana; and serves as an adviser/consultant to Alentis Therapeutics, AstraZeneca, Black Diamond, Exelixis, Genentech, H3Biomedicine, Incyte Corporation, Kinnate, QED Therapeutics, Servier, Sirtex Medical Ltd, TranstheraBio and Taiho Oncology Inc. N.B. receives research funding from Kinnate Biopharma, Taiho Oncology, Relay, Bristol Myers Squibb and Servier Laboratories. T.F.G. receives research funding (to institution) from Merck and AstraZeneca. R.S., X.W.W. and L.M. declare no competing interests.
